-
Something wrong with this record ?
Novel sulfonamide incorporating piperazine, aminoalcohol and 1,3,5-triazine structural motifs with carbonic anhydrase I, II and IX inhibitory action
E. Havránková, J. Csöllei, D. Vullo, V. Garaj, P. Pazdera, CT. Supuran,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Amino Alcohols chemistry pharmacology MeSH
- Antigens, Neoplasm metabolism MeSH
- Carbonic Anhydrase Inhibitors chemical synthesis chemistry pharmacology MeSH
- Carbonic Anhydrase I antagonists & inhibitors metabolism MeSH
- Carbonic Anhydrase II antagonists & inhibitors metabolism MeSH
- Carbonic Anhydrase IX antagonists & inhibitors metabolism MeSH
- Humans MeSH
- Molecular Structure MeSH
- Piperazine chemistry pharmacology MeSH
- Sulfonamides chemistry pharmacology MeSH
- Triazines chemistry pharmacology MeSH
- Dose-Response Relationship, Drug MeSH
- Structure-Activity Relationship MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
A new series of s-triazine derivatives incorporating sulfanilamide, homosulfanilamide, 4-aminoethyl-benzenesulfonamide and piperazine or aminoalcohol structural motifs is reported. Molecular docking was exploited to select compounds from virtual combinatorial library for synthesis and subsequent biological evaluation. The compounds were prepared by using step by step nucleophilic substitution of chlorine atoms from cyanuric chloride (2,4,6-trichloro-1,3,5-triazine). The compounds were tested as inhibitors of physiologically relevant carbonic anhydrase (CA, EC 4.2.1.1) isoforms. Specifically, against the cytosolic hCA I, II and tumor-associated hCA IX. These compounds show appreciable inhibition. hCA I was inhibited with KIs in the range of 8.5-2679.1 nM, hCA II with KIs in the range of 4.8-380.5 nM and hCA IX with KIs in the range of 0.4-307.7 nM. As other similar derivatives, some of the compounds showed good or excellent selectivity ratios for inhibiting hCA IX over hCA II, of 3.5-18.5. 4-[({4-Chloro-6-[(4-hydroxyphenyl)amino]-1,3,5-triazin-2-yl}amino)methyl] benzene sulfonamide demonstrated subnanomolar affinity for hCA IX (0.4 nM) and selectivity (18.50) over the cytosolic isoforms. This series of compounds may be of interest for the development of new, unconventional anticancer drugs targeting hypoxia-induced CA isoforms such as CA IX.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19012920
- 003
- CZ-PrNML
- 005
- 20190409163055.0
- 007
- ta
- 008
- 190405s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.bioorg.2017.12.034 $2 doi
- 035 __
- $a (PubMed)29324250
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Havránková, Eva $u University of Veterinary and Pharmaceutical Sciences, Faculty of Pharmacy, Department of Chemical Drugs, Palackého 1-3, CZ-612 42 Brno, Czech Republic; Masaryk University, Faculty of Science, Department of Chemistry, Centre for Syntheses at Sustainable Conditions and Their Management, University Campus, Kamenice 753/5, CZ-625 00 Brno, Czech Republic. Electronic address: havrankova.e@mail.muni.cz.
- 245 10
- $a Novel sulfonamide incorporating piperazine, aminoalcohol and 1,3,5-triazine structural motifs with carbonic anhydrase I, II and IX inhibitory action / $c E. Havránková, J. Csöllei, D. Vullo, V. Garaj, P. Pazdera, CT. Supuran,
- 520 9_
- $a A new series of s-triazine derivatives incorporating sulfanilamide, homosulfanilamide, 4-aminoethyl-benzenesulfonamide and piperazine or aminoalcohol structural motifs is reported. Molecular docking was exploited to select compounds from virtual combinatorial library for synthesis and subsequent biological evaluation. The compounds were prepared by using step by step nucleophilic substitution of chlorine atoms from cyanuric chloride (2,4,6-trichloro-1,3,5-triazine). The compounds were tested as inhibitors of physiologically relevant carbonic anhydrase (CA, EC 4.2.1.1) isoforms. Specifically, against the cytosolic hCA I, II and tumor-associated hCA IX. These compounds show appreciable inhibition. hCA I was inhibited with KIs in the range of 8.5-2679.1 nM, hCA II with KIs in the range of 4.8-380.5 nM and hCA IX with KIs in the range of 0.4-307.7 nM. As other similar derivatives, some of the compounds showed good or excellent selectivity ratios for inhibiting hCA IX over hCA II, of 3.5-18.5. 4-[({4-Chloro-6-[(4-hydroxyphenyl)amino]-1,3,5-triazin-2-yl}amino)methyl] benzene sulfonamide demonstrated subnanomolar affinity for hCA IX (0.4 nM) and selectivity (18.50) over the cytosolic isoforms. This series of compounds may be of interest for the development of new, unconventional anticancer drugs targeting hypoxia-induced CA isoforms such as CA IX.
- 650 _2
- $a aminoalkoholy $x chemie $x farmakologie $7 D000605
- 650 _2
- $a antigeny nádorové $x metabolismus $7 D000951
- 650 _2
- $a karboanhydrasa I $x antagonisté a inhibitory $x metabolismus $7 D024401
- 650 _2
- $a karboanhydrasa II $x antagonisté a inhibitory $x metabolismus $7 D024402
- 650 _2
- $a karboanhydrasa IX $x antagonisté a inhibitory $x metabolismus $7 D000071231
- 650 _2
- $a inhibitory karboanhydras $x chemická syntéza $x chemie $x farmakologie $7 D002257
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a piperazin $x chemie $x farmakologie $7 D000077489
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 650 _2
- $a sulfonamidy $x chemie $x farmakologie $7 D013449
- 650 _2
- $a triaziny $x chemie $x farmakologie $7 D014227
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Csöllei, Jozef $u University of Veterinary and Pharmaceutical Sciences, Faculty of Pharmacy, Department of Chemical Drugs, Palackého 1-3, CZ-612 42 Brno, Czech Republic.
- 700 1_
- $a Vullo, Daniela $u University of Florence, Polo Scientifico, Neurofarba Department, Via Ugo Shiff 6, 500 19 Sesto Fiorentino (Florence), Italy.
- 700 1_
- $a Garaj, Vladimír $u Comenius University in Bratislava, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Odbojárov 10, 832 32 Bratislava, Slovakia.
- 700 1_
- $a Pazdera, Pavel $u Masaryk University, Faculty of Science, Department of Chemistry, Centre for Syntheses at Sustainable Conditions and Their Management, University Campus, Kamenice 753/5, CZ-625 00 Brno, Czech Republic.
- 700 1_
- $a Supuran, Claudiu T $u University of Florence, Polo Scientifico, Neurofarba Department, Via Ugo Shiff 6, 500 19 Sesto Fiorentino (Florence), Italy. Electronic address: claudiu.supuran@unifi.it.
- 773 0_
- $w MED00000771 $t Bioorganic chemistry $x 1090-2120 $g Roč. 77, č. - (2018), s. 25-37
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29324250 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20190409163110 $b ABA008
- 999 __
- $a ok $b bmc $g 1392230 $s 1051225
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 77 $c - $d 25-37 $e 20180103 $i 1090-2120 $m Bioorganic chemistry $n Bioorg Chem $x MED00000771
- LZP __
- $a Pubmed-20190405